Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 16 clinical trials
Mycophenolate Mofetil Versus Azathioprine in Treatment Naive Autoimmune Hepatitis (CAMARO)

. Secondary endpoints include safety and tolerability of mycophenolate mofetil, time to remission, changes in Model For End-Stage Liver Disease (MELD) -score (and its components bilirubin, INR, creatinine

remission
prednisolone
pseudocholinesterase
azathioprine
mycophenolate
  • 32 views
  • 15 Jun, 2022
  • 14 locations
A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver-related Outcomes in Patients With Well-compensated (Child-Pugh A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis (MAESTRO-NASH OUTCOMES)

This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical Outcome event.

fibrosis
  • 0 views
  • 21 Oct, 2022
  • 1 location
New Prognostic Predictive Models of Mortality of Decompensated Cirrhotic Patients Waiting for Liver Transplantation (SUPERMELD)

The MELD score is a predictive model of cirrhosis mortality used in France since 2007 to prioritize access to liver transplantation for patients enrolled in the national waiting list. The

meld score
cirrhosis
liver transplant
  • 0 views
  • 13 May, 2022
  • 1 location
Tocotrienol Against the Progression of End Stage Liver Disease

The purpose of this Phase 2 trial is to validate the outcome observed in a previous trial that oral Tocotrienol (TCT) attenuates the rise in MELD score over time in patients with end stage liver

meld score
nash
cirrhosis
fatty liver
tocotrienol
  • 232 views
  • 21 Mar, 2022
  • 1 location
Umbilical Cord-derived Mesenchymal Stem Cell Infusion in the Management of Adult Liver Cirrhosis

This is a phase I, open label, single arm trial using UC-MSCs to treat patients with liver cirrhosis that includes 20 patients. The primary outcome measure will be change in MELD score at 3, 6

meld score
biopsy of liver
esophageal varices
  • 0 views
  • 06 May, 2022
  • 1 location
Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B

steatosis/inflammation, regress ascites (a cirrhotic complication), and improve liver function parameters and survival prognosis in terms of model for end-stage liver disease (MELD) score. There are

elastography
cirrhosis
fibroscan
ascites
hepatitis
  • 0 views
  • 14 Jun, 2022
  • 1 location
DUR-928 in Patients With Alcoholic Hepatitis (DUR-928/AH)

The proposed study is An Open-Label, Dose Escalation Study to Assess the Safety, and Pharmacodynamics (PD) signals of DUR 928 in Patients with AH. DUR-928 will be administered in 100 mL 5% dextrose or 0.9% sodium chloride by slow intravenous infusion over 2 hrs (50mL/h) until entire dose is given …

  • 0 views
  • 04 Oct, 2022
  • 1 location
Study of Decompensated Alcoholic Cirrhosis Treatment by Stem Cells

The main purpose of this study is to evaluate the safety and tolerance of umbilical cord mesenchymal stem cells (UCMSCs) in patients with decompensated alcoholic cirrhosis, and to provide dose basis for subsequent clinical study design. We will also explore the possible mechanism of UCMSCs in the treatment of decompensated …

encephalopathy
meld score
hepatitis
prothrombin
gastrointestinal hemorrhage
  • 0 views
  • 13 Jul, 2022
  • 1 location
Dual Hypothermic Oxygenated Machine Perfusion in Liver Transplantation Using Allografts From Donors After Brain Death

This will be a randomized study on the effects of hypothermic oxygenated machine perfusion in patients undergoing liver transplantations from donors after brain death with allocation of patients to either end-ischemic hypothermic oxygenated machine perfusion group (at least 2 hours of allograft perfusion at 12 degrees Celsius though hepatic artery …

  • 0 views
  • 19 Apr, 2021
  • 1 location
Assessment of the Efficacy of Lenvatinib Versus Sorafenib in the Management of Advanced Hepatocellular Carcinoma

Hepatocellular carcinoma is the most common type of liver cancer, which is the 3rd leading cause of cancer deaths worldwide. The incidence is expected to increase as a consequence of chronic liver disease with its multiple risk factors, including chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, …

cancer
erlotinib
TACE
tyrosine
  • 0 views
  • 02 Jun, 2022
  • 1 location